Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Enzyme Inhibitor	NCIT_C471	[A pharmacological agent that inhibits the catalytic activity of an enzyme.]
Acquisition Duration	NCIT_C69269	[The amount of time elapsed during the capture of data.]
Duration	NCIT_C25330	[The period of time during which something continues.]
Alpelisib	NCIT_C94214	[An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.]
Phosphatidylinositide 3-Kinase Inhibitor	NCIT_C2152	[Any substance that inhibits phosphatidylinositol 3-kinase (phosphatidylinositide 3-kinase), an enzyme that catalyzes the phosphorylation of the 3 position hydroxyl group of the inositol ring of phosphatidylinositol and functions as an intracellular signal transducer in cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. Inhibition of phosphatidylinositol 3-kinase produces antiproliferative and antiangiogenic effects.]
Indoleamine 2,3-dioxygenase Peptide Vaccine	NCIT_C94215	[A peptide vaccine against the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), with potential immunomodulating and antineoplastic activities. Vaccination with indoleamine 2,3-dioxygenase peptide vaccine may activate the immune system to induce an immune response against IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and may eradicate IDO-expressing tumor cells. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression; Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system.]
GITRL RNA-transfected Autologous Dendritic Cell Vaccine	NCIT_C94216	[An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. GITRL RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of GlTRL results in modulating T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.]
Dendritic Cell Vaccine	NCIT_C28310
Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine	NCIT_C94217	[An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.]
Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine	NCIT_C94218	[An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.]
Anti-CD30/CD16A Monoclonal Antibody AFM13	NCIT_C94219	[A tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Anti-CD30/CD16A monoclonal antibody AFM13 binds to the CD16A expressed on natural killer (NK) cells with two of its binding sites and to CD30 on CD30-expressing tumor cells with the other two binding sites, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation, antibody-dependent cellular cytotoxicity (ADCC) and eventually tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is overexpressed in hematologic malignancies; CD16A is specifically expressed on the surface of NK cells.]
Antineoplastic Antibody	NCIT_C129822	[Any type of antibody that exerts antineoplastic activity.]
Monoclonal Antibody	NCIT_C20401	[An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.]
Subject Age	NCIT_C69260	[The age of a person who is the subject in a study.]
Performed Procedure Step SOP Instance UID	NCIT_C69261	[The unique identifier for an instance of a performed procedure step.]
Performed Procedure Step SOP Class UID	NCIT_C69262	[The unique identifier for a performed procedure step class.]
Drug Finished Identifier	NCIT_C69274	[An identifier for a drug for which administration has ended.]
Drug Administered Identifier	NCIT_C69275	[An identifier for a drug that was administered.]
Contrast Agent Started Identifier	NCIT_C69276	[An identifier for a contrast agent for which administration has started.]
Contrast Agent Finished Identifier	NCIT_C69277	[An identifier for a contrast agent for which administration has ended.]